Why do ARBs cause significantly less cough and angioedema than ACE inhibitors?
Choose an answer, then check it.
Clinical Pharmacology · Antihypertensive Medications
ARBs
On this page 6 sections
In 30 seconds
Angiotensin II receptor blockers (ARBs) — the "-sartan" drugs like losartan, valsartan, irbesartan, candesartan, olmesartan, and telmisartan — block the same renin-angiotensin-aldosterone system as ACE inhibitors, but at a different point: they sit on the AT1 receptor instead of stopping the enzyme that makes angiotensin II. That single difference in mechanism is why ARBs cause far less cough and angioedema than ACE inhibitors, making them the go-to substitute when a patient can't tolerate an ACE inhibitor. Everything else — the indications, the cautions, the pregnancy contraindication — carries over almost unchanged from the ACE inhibitor class.
The college version
Mechanism: blocking the receptor, not the enzyme
The renin-angiotensin-aldosterone system (RAAS) raises blood pressure through angiotensin II, a peptide that causes vasoconstriction and stimulates aldosterone release. ACE inhibitors work upstream, blocking the angiotensin-converting enzyme that produces angiotensin II from angiotensin I. ARBs work downstream: they bind directly to the AT1 receptor on vascular smooth muscle and the adrenal gland, competitively blocking angiotensin II from acting there — regardless of how much angiotensin II is circulating. The net physiologic effect is nearly identical to an ACE inhibitor: vasodilation, reduced aldosterone secretion, lower blood pressure, and reduced strain on the heart and kidneys.
Why the cough and angioedema drop out
ACE inhibitors cause a dry cough in a meaningful minority of patients, and rarely trigger angioedema, because the same enzyme they block (ACE, also called kininase II) is also responsible for breaking down bradykinin. Blocking ACE lets bradykinin accumulate in the airways and tissues, and bradykinin is the culprit behind both the cough and the swelling. ARBs never touch that enzyme — bradykinin metabolism proceeds normally — so this side effect pathway is essentially absent. This is the single most clinically important distinction between the two classes, and it is why ARBs exist as a class at all: they were developed to give ACE inhibitor–level RAAS suppression without the bradykinin-driven side effects.
Shared indications
Because they act on the same pathway, ARBs are used for the same core conditions as ACE inhibitors: hypertension, heart failure with reduced ejection fraction, diabetic kidney disease and proteinuria (they are renal-protective independent of their blood-pressure-lowering effect), and post-myocardial-infarction cardiac remodeling. In practice, an ARB is most often chosen as the substitute when a patient develops a cough on an ACE inhibitor, since switching classes typically resolves the cough while preserving the therapeutic benefit.
Losartan's extra effect
Losartan has a distinguishing property not shared by the rest of the class: it has a mild uricosuric effect, meaning it promotes uric acid excretion by the kidneys. This makes it a reasonable preferential choice in a hypertensive patient who also has gout or hyperuricemia, though it is not used as a primary gout treatment.
Shared cautions
ARBs carry the same warnings as ACE inhibitors. Because they suppress aldosterone, they can cause hyperkalemia. Because they dilate the efferent arteriole of the glomerulus, they can precipitate acute kidney injury in patients with bilateral renal artery stenosis or significant volume depletion, where glomerular filtration depends on angiotensin II-mediated efferent constriction. They can cause symptomatic hypotension, especially with the first dose or in volume-depleted patients. And they are absolutely contraindicated in pregnancy, since fetal exposure to RAAS blockade is associated with serious renal and other developmental injury.
The no-combination rule
ACE inhibitors and ARBs should not be combined. Both suppress the same pathway, and dual blockade dramatically increases the risk of hyperkalemia, hypotension, and acute kidney injury without a proven added benefit for most patients. Clinical practice treats these two classes as interchangeable alternatives, not additive partners.
Sacubitril-valsartan
Sacubitril-valsartan pairs an ARB (valsartan) with neprilysin inhibition, giving a combined angiotensin receptor–neprilysin inhibitor (ARNI) used in heart failure with reduced ejection fraction. Neprilysin normally degrades natriuretic peptides, so inhibiting it boosts their beneficial diuretic and vasodilatory signaling. Because neprilysin also breaks down bradykinin, combining it with an ACE inhibitor would risk severe angioedema — this is why a washout period is required when switching a patient from an ACE inhibitor to sacubitril-valsartan.
Nursing considerations
Monitor serum potassium and renal function, particularly after starting or increasing the dose, and watch for symptomatic hypotension. Confirm pregnancy status before initiating an ARB in anyone of childbearing potential, and counsel on contraception and reporting a suspected pregnancy immediately. Verify that the patient is not also on an ACE inhibitor.
Eli explains
The same idea, in plain words
Explain it like I’m 10
Picture angiotensin II as a key that fits into a lock (the AT1 receptor) and turning that lock squeezes your blood vessels tight, raising your blood pressure. ACE inhibitors work like a factory that stops making the key in the first place. ARBs work differently: they let the factory keep making keys, but they jam something into the lock itself so the real key can't turn it. Either way, the squeezing stops and blood pressure comes down. But the factory that makes the key also happens to clean up a separate messy chemical (bradykinin) as a side job — so shutting the whole factory down (like an ACE inhibitor does) lets that mess pile up and causes a cough or swelling. Jamming the lock instead (like an ARB does) leaves the factory running fine, so that mess never builds up. That's why ARBs almost never cause the cough that ACE inhibitors sometimes do.
Check yourself
2 review questions from the chapter. Try each one, then open the answer.
A patient with a persistent dry cough on lisinopril is switched to losartan and the cough resolves within a few weeks. Explain, in terms of mechanism, why changing classes fixed the problem.
Show answer
The cough was caused by bradykinin building up because lisinopril blocked the enzyme that normally breaks it down.
Losartan blocks the receptor instead of the enzyme, so bradykinin clearance goes back to normal and the cough goes away, while the blood pressure benefit is preserved through the same downstream pathway.
A patient with heart failure who has been stable on an ACE inhibitor is being considered for a switch to sacubitril-valsartan. What specific precaution must be taken before starting it, and why?
Show answer
A washout period after stopping the ACE inhibitor is required before starting sacubitril-valsartan, because sacubitril inhibits neprilysin, which also degrades bradykinin.
If an ACE inhibitor is still on board when neprilysin gets blocked too, bradykinin can spike from two directions at once, creating a much higher risk of serious angioedema.
Quick check
3 questions here. Answers stay hidden until you check.
Which ARB is notable for an additional uricosuric effect that can benefit patients with coexisting gout?
Choose an answer, then check it.
Why is it inappropriate to combine an ACE inhibitor and an ARB in the same patient?
Choose an answer, then check it.
Study tools & related lessonsRelated
Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.